Research & Educational Use Only. Not medical advice. Not for human consumption.
📈 GH Releasing Peptide

GHRP-2 / Pralmorelin (10 mg Vial) Dosage Protocol

GHRP-2 (Pralmorelin) is a synthetic hexapeptide GH releasing peptide that acts on ghrelin receptors in both the pituitary and hypothalamus. It is among the most potent GHRPs studied, producing robust GH release; unlike ipamorelin, it can mildly elevate cortisol and prolactin at higher doses.

âš¡ Quickstart Highlights

Reconstitution
3.0 mL BAC water → 3.33 mg/mL
Per-Dose Range
100–300 mcg per injection
1 U-100 Unit =
33.3 mcg
Half-life
~15–60 minutes

Dosing & Reconstitution Guide

Route: Subcutaneous or IV  |  Frequency: 1–3× daily, empty stomach

ProtocolDose Per InjectionFrequencyU-100 UnitsNotes
Conservative100 mcgOnce daily3 unitsMinimal cortisol effect
Standard200 mcgTwice daily6 unitsStrong GH pulse
Advanced300 mcg2–3× daily9 unitsPeak GH stimulation; cortisol risk
GHRP-2 stimulates cortisol and prolactin at higher doses — a key distinction from ipamorelin. Researchers using GHRP-2 at 300 mcg+ doses should account for this hormonal profile. Combining with a GHRH analog (CJC-1295) produces synergistic GH release.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl until dissolved. Do not shake.
  4. Refrigerate at 2–8°C; use within 28 days.

Supplies Planning

Item8 Weeks (2×/day)12 Weeks (2×/day)
GHRP-2 vials (10 mg each)5–6 vials8–9 vials
Insulin syringes (30–50 unit)112168
Bacteriostatic water (10 mL)2 × 10 mL3 × 10 mL
Alcohol swabs2–3 × 100-pack3–4 × 100-pack

Mechanism of Action

GHRP-2 (pralmorelin) is a synthetic hexapeptide that acts as a ghrelin receptor (GHS-R1a) agonist. It stimulates GH release through two complementary pathways: directly at the pituitary and by amplifying GHRH release from the hypothalamus. This dual-site action makes it one of the most potent GHRPs studied.

GHRP-2 produces robust GH pulses with peak concentrations at approximately 15–30 minutes post-injection. Unlike ipamorelin, GHRP-2 can produce dose-dependent cortisol and prolactin elevation, particularly at doses ≥300 mcg. This limits its utility in extended protocols where adrenal axis interference is a concern. When combined with GHRH analogs (CJC-1295, Sermorelin), GH pulse amplitude is dramatically amplified through complementary receptor pathway activation.

Research Findings & Safety Profile

Storage

StateTemperatureDurationNotes
Lyophilized−20°C (−4°F)Up to 24 monthsDry, dark, minimize moisture
Reconstituted2–8°C (35–46°F)Up to 28 daysAvoid freeze-thaw
âš  Research Use Only: GHRP-2 is an investigational compound. Cortisol and prolactin elevation at high doses distinguishes it from ipamorelin. All dosing extrapolated from preclinical and diagnostic pharmacological data.

References

1
Bowers CY et al. 'Synergistic release of GH by GHRP-2 and GHRH' — J Clin Endocrinol Metab, 1990 View source ↗
2
Arvat E et al. 'Endocrine activities of ghrelin, a natural GH secretagogue (GHS)' — J Clin Endocrinol Metab, 2001 View source ↗
3
Iwakura H et al. 'Ghrelin's gastrokinetic activity in functional dyspepsia' — as diagnostic context for ghrelin receptor pharmacology View source ↗